» Articles » PMID: 32158531

Accurate 3-gene-signature for Early Diagnosis of Liposarcoma Progression

Overview
Publisher Biomed Central
Date 2020 Mar 12
PMID 32158531
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Well- and dedifferentiated liposarcoma (WD/DDLPS) are rare mesenchymal malignant tumors that account for 20% of all sarcomas in adults. The WD form is a low-grade malignancy with a favourable prognosis which may progress to DDLPS, a high-grade aggressive counterpart. WDLPS is referred to as atypical lipomatous tumour (ALT) when localised in extremities, due to its better prognosis. Currently the final differential diagnosis to distinguish between more aggressive and less aggressive form is based on post-surgical histological examination and no molecular biomarkers for early detection are available.

Methods: Quantitative polymerase chain reaction (qPCR) analysis of 11 metabolic genes involved in general and adipose tissue-specific metabolism, was performed on ALT (= 8), WDLPS (= 9) and DDLPS (= 20) samples. Subsequent statistical analysis was carried out to determine genes that most accurately can predict DDLPS differential diagnosis. Selected genes were further validated in a separate cohort by qPCR and the data statistically analysed. Deep sequencing was performed on DDLPS specimen from the metastatic patient and on five random WDLPS specimens.

Results: We established a three-gene signature based on and , which identified DDLPS with 100% sensitivity and 90% specificity, even in specimens from the WD component of DDLPS tumors. Interestingly, the gene is deleted in 45% of DDLPS samples analyzed under TCGA project, and the deletion is associated with significantly lower expression level. However, other mechanisms causing loss or downregulation of the expression of these three genes may be involved. Moreover, the significantly lower level of PNPLA2 is associated with R1 surgical margins, compare to R0 margins, which suggests the more invasive tumor phenotype in the absence of PNPLA2.

Conclusions: The identified metabolic signature allows highly accurate differential diagnosis between WD- and DDLPS even in samples containing lipid droplets, a marker of differentiation, which makes it very suitable for the use on biopsies. In respect to the pathogenesis of the disease, our results give a new insight into possible molecular mechanisms involved and support the recent observation that deletion of is a novel factor in liposarcoma progression.

Citing Articles

Deciphering the prognostic and therapeutic significance of BAG1 and BAG2 for predicting distinct survival outcome and effects on liposarcoma.

Lian Y, Chen J, Han J, Zhao B, Wu J, Li X Sci Rep. 2024; 14(1):23084.

PMID: 39366981 PMC: 11452671. DOI: 10.1038/s41598-024-67659-6.


The diagnosis, genetic alternation, and treatment of the primary pleomorphic liposarcoma of the femur in a rare age: Case report and literature review.

Wu H, Ghanem A, Abbas K, Abdalshafy H, Abdelazeem B, Wang H Heliyon. 2024; 10(17):e36953.

PMID: 39296074 PMC: 11407983. DOI: 10.1016/j.heliyon.2024.e36953.


Bioinformatics Screen Reveals Gli-Mediated Hedgehog Signaling as an Associated Pathway to Poor Immune Infiltration of Dedifferentiated Liposarcoma.

Beadle E, Bennett N, Rhoades J Cancers (Basel). 2023; 15(13).

PMID: 37444470 PMC: 10341348. DOI: 10.3390/cancers15133360.


Deciphering the Prognostic and Therapeutic Significance of Cell Cycle Regulator CENPF: A Potential Biomarker of Prognosis and Immune Microenvironment for Patients with Liposarcoma.

Chen J, Lian Y, Zhao B, Han J, Li X, Wu J Int J Mol Sci. 2023; 24(8).

PMID: 37108172 PMC: 10139200. DOI: 10.3390/ijms24087010.


Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.

Lu J, Wood D, Ingley E, Koks S, Wong D Mol Biol Rep. 2021; 48(4):3637-3647.

PMID: 33893924 DOI: 10.1007/s11033-021-06362-5.

References
1.
Italiano A, Toulmonde M, Cioffi A, Penel N, Isambert N, Bompas E . Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol. 2011; 23(6):1601-7. DOI: 10.1093/annonc/mdr485. View

2.
Smith C, Martinez S, Tseng W, Tamurian R, Bold R, Borys D . Predicting survival for well-differentiated liposarcoma: the importance of tumor location. J Surg Res. 2011; 175(1):12-7. DOI: 10.1016/j.jss.2011.07.024. View

3.
Livingston J, Bugano D, Barbo A, Lin H, Madewell J, Wang W . Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep. 2017; 7(1):11836. PMC: 5605500. DOI: 10.1038/s41598-017-12132-w. View

4.
Beird H, Wu C, Ingram D, Wang W, Alimohamed A, Gumbs C . Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. Cold Spring Harb Mol Case Stud. 2018; 4(2). PMC: 5880260. DOI: 10.1101/mcs.a002386. View

5.
Wu J, Preuss C, Wang S, Yang H, Ji B, Carter G . Epistatic interaction between the lipase-encoding genes Pnpla2 and Lipe causes liposarcoma in mice. PLoS Genet. 2017; 13(5):e1006716. PMC: 5432192. DOI: 10.1371/journal.pgen.1006716. View